Financial Barriers to Organ Transplantation: A Comparative Analysis by Renkes, Ashley C
SPNHA Review
Volume 8 | Issue 1 Article 5
1-1-2012
Financial Barriers to Organ Transplantation: A
Comparative Analysis
Ashley C. Renkes
Grand Valley State University
Follow this and additional works at: http://scholarworks.gvsu.edu/spnhareview
Copyright ©2012 by the authors. SPNHA Review is reproduced electronically by ScholarWorks@GVSU. http://scholarworks.gvsu.edu/
spnhareview?utm_source=scholarworks.gvsu.edu%2Fspnhareview%2Fvol8%2Fiss1%2F5&utm_medium=PDF&utm_campaign=PDFCoverPages
Recommended Citation
Renkes, Ashley C. (2012) "Financial Barriers to Organ Transplantation: A Comparative Analysis," SPNHA Review: Vol. 8: Iss. 1,
Article 5.
Available at: http://scholarworks.gvsu.edu/spnhareview/vol8/iss1/5
Renkes/Financial Barriers to Organ Transplantation                                               
 
33 
 
 
FINANCIAL BARRIERS TO ORGAN TRANSPLANTATION: A COMPARATIVE 
ANALYSIS 
 
ASHLEY C. RENKES 
Grand Valley State University 
 
 
ABSTRACT 
 
Organ procurement and transplantation is an expensive process. Because of economic concerns, 
hospitals often refuse to list otherwise qualified patients for transplant unless that patient has the 
financial means to pay for the transplant and related services. This prevents patients from 
receiving lifesaving organ transplants even when they are medically qualified. Since the 
financial aspect of transplant is a concern in the United States, this paper explores the origin of 
the barriers, and through the literature compares barriers to those in other countries performing 
organ transplants. It also explores ways for patients to overcome financial barriers to 
transplantation.  
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INTRODUCTION 
 
   Capitalism reserves goods for those that can afford to buy them. In the case of organ donation 
in the United States, it is illegal to buy or sell organs; however, a significant economy exists 
surrounding the business of procuring and transplanting organs. The transplant recipient incurs 
all charges related to organ procurement and transplantation. This creates an enormous burden 
for the patient or his insurance provider. Obtaining funding for an organ transplant can be the 
difference between life and death for patients who don’t have adequate health insurance, or lack 
health insurance. 
   Major religions, organ procurement organizations (OPO), and transplant centers consider organ 
donation a benevolent act. Despite this, the price tag affixed to each lifesaving organ is far from 
benevolent. While we (as a society) shift the cost of procurement and transplantation away from 
the donor and her family, we don’t always consider the burden for the transplant recipient. 
Defining financial barriers to solid organ transplant as: A condition related to paying for an 
organ transplant that if not met, precludes the patient from receiving a solid organ transplant; it is 
important to understand the charges associated with organ transplant and their origins in order to 
grasp the burden placed on patients who need lifesaving transplants. It is also necessary to 
understand the financial burden in order to explore alternatives for funding procedures and 
medications associated with transplantation, noting that payment for organ transplants is a 
subjective arrangement defined by the specific transplant center treating the patient, and 
necessary conditions may vary from center to center.  
   Most importantly, we can learn from and compare the American transplant system to other 
developed countries with modern healthcare systems. There is a principal question in this paper: 
What financial barriers to solid organ transplantation exist; and comparatively, do Americans 
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face more financial barriers to transplantation than patients in other developed nations with 
modern healthcare systems? These issues are explored considering the current limitations of 
living and deceased organ donor availability, and the realities of profit in the American 
healthcare system.  
 
  
ORGAN PROCUREMENT AND TRANSPLANT OVERVIEW 
 
Procurement and Transplantation 
 
   Procurement and transplantation are two unique processes in the American donation and 
transplantation system. Organ procurement encompasses donor evaluation, obtaining consent for 
donation, medically managing the donor, and placing the organs with transplant centers 
according to United Network for Organ Sharing (UNOS) policy. Currently, UNOS indicates over 
111,000 patients are waiting for an organ transplant (a number which increases by thousands of 
patients every year), while numbers of organs donors remain relatively static over time (OPTN 
2009).  
   Organ procurement is managed by one of 58 federally designated OPOs who are either 
independent nonprofit organizations or nonprofits associated with a major university (e.g. the 
University of Wisconsin). Transplantation occurs after a transplant center (a hospital that 
performs organ transplants) accepts an organ from a donor managed by an OPO. Typically, the 
transplant center’s surgeons surgically recover an organ for their patient. Alternatively, the OPO 
can arrange for a compensated, qualified, third-party surgeon to recover the organ. The organ is 
then transported back to the transplant center and the transplant surgery is performed on the 
recipient. All of the costs related to donor’s medical management, the procurement of a specific 
organ, and the transplant surgery are billed to the recipient via the transplant center. The 
distribution of charges is a complex process managed by the OPO in collaboration with the 
transplant center and donor hospital.  
 
Aftercare and Medication 
  
   Aside from charges associated with organ procurement and transplantation procedures, there is 
a significant cost associated with the recipient’s aftercare and anti-rejection medication. This 
adds an onerous annual expense to the existing financial burden associated with the transplant 
surgery. Many transplant centers include the cost of anti-rejection medication in their assessment 
of a patient’s ability to pay for a transplant.  This additional consideration increases the 
likelihood that a patient won’t have the appropriate funds for their transplant, and won’t be listed 
at a transplant center because of their financial status. Transplant centers often require proof of 
assets or adequate health insurance to consider listing a patient with UNOS. The rationale behind 
this practice is to ensure that the patient will have appropriate aftercare, and be able to afford 
their anti-rejection medication. It also ensures that the transplant center is reimbursed for its 
expenditures related to the donation. 
   Although this process may seem fair and equitable for reimbursing involved parties, it often 
presents such an enormous burden for the patient and her family that she is unable to survive the 
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process of finding insurance or other funds, and becomes one of 16-17 people who die each day 
waiting for an organ transplant (OPTN 2009). 
 
Expenditures Associated with Transplantation and Related Processes 
 
   In 2008 the Milliman firm developed an actuarial report that outlined the total cost of solid 
organ transplant. In the report, Milliman uses data provided by the Organ Procurement and 
Transplant Network (OPTN), whose programs are currently managed by UNOS. Milliman 
(2008) averaged costs associated with all transplantations performed on American citizens the 
year prior, and estimates the cost of procurement according to 2005 and 2006 data from Texas 
and Washington based OPOs. The firm included the following data: thirty days of pre-transplant 
hospitalization and associated charges; procurement services; hospital charges associated with 
the transplant; physician’s fees; 180 days post-transplant hospital admission (initial 
hospitalization and repeat hospitalization after initial discharge, and outpatient procedures and 
laboratory services); and the cost of medication (anti-rejection, etc.) associated with pre and 
post-transplant prescriptions within 180 days (Milliman 2008). This thorough analysis of the 
overall cost of obtaining an organ transplant is the basis for further analysis. 
  The intestine is the most expensive single organ transplant, averaging $1,121,800 per transplant 
(Milliman 2008). The kidney is the least expensive at only $259,900. Other transplants range 
from $275,500 to $787,700 per organ (Milliman 2008). Multiple organ transplants escalate these 
costs to well over the million-dollar mark, with the exception of liver-kidney and kidney-
pancreas transplants. Lung transplants are considered single organ transplants whether or not 
both lungs are transplanted into the same recipient, and Milliman provides estimates for both 
single and double lung transplants. It is important to note that Milliman assumed in their 
calculations that these charges are associated with patients with full-coverage insurance 
(Milliman 2008). The total cost for a private-pay patient could be much higher without the 
benefit of an insurance company’s negotiated rate agreements. In Chisholm (2007), a 2001 
survey conducted by the author indicated that the first year of post-transplant medication 
exceeded $20,000. In Chisholm (2005), the estimate stood at $12,000 per year in the years 
following the initial post-transplant year. This data is also reflected in the Milliman (2008) study.  
  There is an argument within the transplant community that only those who have the ability to 
take care of their organ post-transplant should be listed at a transplant center. Because of this 
consideration, and the economic needs of the hospital, finances appear among the various and 
extensive criteria used to assess the health status of a potential transplant patient. With a noted 
increase in patients waiting for a transplant, and relatively stable donation rates, it is apparent 
transplant centers have some place to be “picky” about their patients (Pomfret et al. 2007). For 
example, the state of Michigan has approximately 3,000 patients waiting for an organ per month, 
and approximately 300 donors per year donating approximately 950 organs (OPTN 2009). With 
no shortage of transplant business and a large shortage of organs, some could argue that only the 
“best” candidates should receive organ transplants.  
 
If the transplant center wants to improve its cost structure, it will probably have to 
transplant only better candidates with better organs so that the patients will have short 
lengths of stays and use fewer resources. But transplant volume may decrease (Howard 
2007). 
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On the other hand, considering the financial assets or insurance of a patient in the listing process 
could prevent patients who are very medically suitable for donation (“better candidates”) from 
receiving their life saving transplants. 
   The importance of finance in transplant is apparent in the materials provided to transplant 
patients by Tulane Medical Center in New Orleans, Louisiana:  
 
The staff at the Tulane Abdominal Transplant Institute (TATI) understand the importance 
of considering the financial aspects of organ transplantation. Because of this, we have 
included financial issues in our patient care services…[Transplant Financial Counselors] 
collaborate and communicate with the Insurance Companies, Medicare and Medicaid 
offices, and with the clinical and social services of the transplant team to provide a 
complete financial plan of care for each individual patient . Most patients cannot afford a 
transplant without some type of health insurance coverage (Tulane 2009).  
 
This is strong language defining the importance of money in the process of being listed at a 
transplant center and subsequently receiving a transplant. While transplant centers are often 
willing to work with patients to secure funding, some patients don’t survive the lengthy process.  
 
Hospital administrators want both high volume and outstanding results. But they also want 
the program to have an ‘excess of revenues over expenses’ (not-for-profit hospitals do not 
have ‘profits’) (Howard 2007). 
 
If a patient doesn’t have the financial resources to pay for a transplant and associated care and 
medications, transplant centers will not place a patient on the waiting list despite the ability to 
save his life with a transplant. 
 
 
COMPARATIVE FINANCIAL ANALYSIS AND BARRIERS OUTSIDE THE U.S. 
 
   Hospitals in the United States are not unique in their ability to perform organ transplants. Many 
other countries perform organ transplants successfully. Comparatively, do other countries’ 
citizens face the same financial considerations when confronted with organ transplantation? 
 
Italy 
 
   Comparatively, Italy’s transplant rates are much lower than the United States; Italy transplants 
19 per million population while the United States transplants 24 per million (Miceli 2000). 
Miceli (2000) studied a patient’s level of education as a socio-economic indicator related to 
organ donation. The results of the study showed that despite free healthcare and organ 
transplantation in Italy (on all accounts, an absence of economic barriers), the absence did not 
reduce the level of discrimination in access to transplant (Miceli 2000). It is interesting to note 
when considering the burden of cost related to American transplants that there were still other 
barriers associated with transplant in Italy, preventing people from being transplanted when 
appropriate. Other barriers included community support of organ donation, with the level of 
community education as a strong indicator for or against organ donation support. 
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Japan 
 
   The Japanese enjoy relatively healthy lives and the third longest average lifespan in the world 
at 82.12 years (CIA World Factbook 2009). Healthcare is accessible, and insurance is affordable 
(Fukuhara 2007). The Japanese do not pay significant out-of-pocket healthcare expenses, and 
insurance co-pays are capped per month. Despite this relative affordability, Japanese citizens 
also have barriers to organ transplantation: 
 
Experts from various fields have hypothesized why organ transplant rates are so low in 
Japan and why so few are from donation after brain death (DBD) donors. Several of their 
theories stem from spiritual beliefs…Others, including members of congress and some 
physician groups, believe that a DBD donor still contains a spirit. Under this belief system, 
removing organs from a DBD donor is equivalent to murder...even today, physicians who 
perform organ transplantation are sometimes sued for their actions (Fukuhara 2007). 
 
Further confounding the lack of organ donations and transplants in Japan is the nation’s cultural 
opposition to brain dead organ donation. From 1968 to 1999 there were no brain dead organ 
donors in Japan (Sato 1999). In 1992 the Japanese government determined that brain death was 
in fact death, but cultural taboos surrounding the condition of a dead patient with a heartbeat 
continued to create a non-financial barrier to donation (Sato 1999). Nearly 300 Japanese citizens 
sought solid organ transplants outside of Japan in those years (Sato 1999). Donation after cardiac 
death (patients declared death by cardio-respiratory means) supplied kidneys to Japanese donors 
during this time. Japan’s transplants per million have not been adequately reported in the 
literature, and donation remains a relatively taboo subject. 
   Japanese citizens still face a shortage of transplant services even without financial barriers. 
Unfortunately, without major cultural change in Japan, whole organ transplant will remain an 
unusual occurrence (Fukuhara 2007).  
 
The United Kingdom 
 
   The United Kingdom lags behind the United States, Spain, and Italy with only 13 transplants 
per million (Rudge 2006). The United Kingdom publicly funds healthcare for all residents with 
tax dollars. Some residents choose to supplement their government funded healthcare with 
private insurance in order to circumvent wait times and public facilities. Patients in need of an 
organ transplant are not faced with financial barriers. Transplant patients in the United Kingdom 
face issues related to a low supply of transplantable organs (Rudge 2006). A lack of physician 
consensus on the appropriate time to declare brain death results in fewer patients being 
considered for organ donation overall, despite the ability for a patient to become a donor after 
cardiac death (Rudge 2006). Patients that donate after cardiac death are typically only able to 
donate livers and kidneys, creating a shortage of other organs if brain dead donors are not 
available. Of all brain dead patients eligible to donate their organs, organ donation officials only 
approach 85 percent of patients’ families about donation (Rudge 2006). Out of the 85 percent of 
all organ donor families approached for donation, 41 percent declined donation (Rudge 2006). 
Again, despite a lack of financial barriers, patients in the UK face organ shortages that result in 
fewer transplanted organs per million than in the United States.    
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Spain 
 
   Spain excels in the area of organ donation. Spain’s presumed consent system results in 
significantly higher consent rates for donation than other developed countries; as a result, Spain 
has 33 transplants per million population (Matesanz 2009). The Spanish single-payer healthcare 
system provides free care to all residents: 
The most common complaint of patients is the long wait to see specialists and undergo 
certain procedures. On the other hand, a study published last year in the U.S. journal Health 
Affairs found that in Spain, there are a third fewer deaths caused by delayed access to health 
care than in the United States. Spain's constitution, drawn up in 1978 following the Franco 
dictatorship, not only guarantees the right to universal health care, it also requires the state 
to provide it. The World Health Organization's ranking system puts Spain's health care 
system seventh in the world, well ahead of America, even though it spends much less on 
health care (Socolovsky 2009). 
Like the United Kingdom, Spanish residents also have the option of supplementing their free 
healthcare with private pay insurance (Socolovsky 2009). Access to private pay insurance may 
expedite a patient’s initial assessment for transplantation, but Spanish residents, like those in the 
United Kingdom, cannot be turned away from a transplant waiting list because of their inability 
to pay. Spanish patients do cover the burden of some of their medication costs; however, this is 
not considered a significant cost within the Spanish transplant system, known as the world’s best 
(Socolovsky 2009). 
 
DISCUSSION 
 
   These comparisons offer perspective on the financial barriers effecting patients in the United 
States; however, any barriers to transplant result in additional preventable deaths. It is important 
to overcome barriers of any origin to maximize a patient’s chances of receiving a lifesaving 
organ. The comparisons between the American transplant system and other developed countries 
are limited by the profit-driven nature of the American medical culture. Developed healthcare 
systems in the United Kingdom, Japan, Spain, and Italy offer either low-cost health insurance or 
are engaged in single-payer government-funded systems. Despite these differences, it is apparent 
that while the primary barrier to transplantation in the United States (other than a shortage of 
organs) is financial in nature; other developed countries face non-financial barriers that restrict 
their relative rates of organ donation and transplantation. Excluding Spain, the United States is 
still able to transplant more organs per million population than any other healthcare system in 
this comparison. The keen difference lies in the ethical nature of financial barriers and a patient’s 
ability or inability to pay as the line between life and death. In single-payer government funded 
healthcare systems and systems with easily accessible affordable healthcare insurance, every 
patient has roughly the same access to healthcare services where they would receive services 
based on organ availability.  
   In Jacobson and Mathur (2010), the competing values of profit and mission in healthcare are 
explored in the context of improving healthcare delivery through health law. Economic realities 
of the market force hospitals to compete for patients and resources (Jacobson and Mathur 2010). 
The American hospital’s need to remain financially viable in order to serve a patient population 
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is especially relevant to the conundrum of financial barriers in organ transplantation. Without 
radical public policy reforms that move the United States into a single-payer government 
healthcare system, or into a system that offers widespread affordable healthcare insurance plans, 
Americans have to work with the existing systems of organ procurement and transplantation. It 
stands that without profit, or some source of revenue to sustain operations, a transplant center 
would cease to exist, removing an important healthcare resource from the community (Jacobson 
and Mathur 2010). Although the other countries in this analysis may have more consistent access 
to transplant services because of the nature of their payment systems, their other barriers to 
transplantation result in systems where fewer organs are transplanted per capita than in the 
United States; Spain being the exception, enjoying the fruit of a presumed-consent culture of 
donation. Ideally, a system that combined the donation culture of the United States and Spain 
(increasing available organs for transplant) and the payment systems of Spain and its 
counterparts (roughly leveling the financial playing field) would provide the best possible 
conditions for receiving an organ transplant in our current age of medical technology. 
 
APPROACHES TO OVERCOMING FINANCIAL BARRIERS 
 
   Barriers to being listed for a possible organ transplant emerge as patients face financial 
obstacles. Finances related to the actual procedures and medications have been discussed at 
length; however, there are a number of ways patients can supplement their own assets or 
insurance in order to qualify for transplantation. In Chisholm (2007), the author explores a 
problem associated with the high cost of transplant: “One of the leading causes of nonadherence 
among renal transplant recipients is the high cost of posttransplant medications, including 
immunosuppressant agents and medications to treat comorbid conditions” (Chisholm 2007). 
“Medication Assistance Programs” for transplant recipients (like the Michigan-based grants 
funded by the Gift of Life Foundation) result in better organ function over time, and increase the 
likelihood that a patient will treat transplant-jeopardizing co-morbidities and reduce their overall 
financial burden (Chisholm 2007). Reducing the patient’s financial burden can help him obtain 
the transplant services he desperately needs. Chisholm (2007) also notes that there are a number 
of ways to obtain assistance with medication costs, including: commercial prescription 
insurance, Medicare, Medicaid, private foundations, and pharmaceutical company medication 
assistance programs. 
   In addition to help with the cost of transplant related medications, Medicare, Medicaid, and 
Veteran’s Tricare all pay toward the cost of solid organ transplant. For individuals eligible for 
Medicare under the End Stage Renal Disease diagnosis, the total cost of transplantation is 
covered. In addition, though Medicaid programs vary by state, there is Medicaid insurance 
available to non-elderly and elderly individuals who are indigent and need an organ transplant 
(Center for Medicare and Medicaid Services 2009). 
   By overcoming these financial barriers to transplant, patients are able to qualify for transplant 
center lists and receive organ transplants. This eliminates the inequality seen in transplantation, 
and gives every patient a fair chance of receiving an organ. Additional support from the 
transplant center through case management workers, social workers, and other coordinators helps 
patients obtain necessary insurance in a timely fashion. With the possibility of insurance 
enrollment denial, it is important that patients facing terminal illness without organ 
transplantation seek out sources of funding for both the transplant and their medication before it 
is too late in their disease process. 
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Medical Tourism 
 
   Transplant medical tourism is an ethically controversial way for patients to obtain cheaper 
organ transplants, often more quickly than in their developed home countries with modern 
healthcare systems. For patients who are poor or lack adequate health insurance, seeking 
overseas transplants not covered by Medicare or Medicaid might offer a cheaper alternative 
when the other option is to die in the United States (Bramstedt and Xu 2007). Transplants 
performed in China and India are a fraction of the cost of American transplants, and private 
insurance groups have encouraged transplant tourism to reduce the initial surgical cost of 
transplantation (Bramstedt and Xu 2007). Organs used in transplant tourism are recovered from 
living and deceased donors. Typically deceased donor organs are reserved for patients within the 
country’s normal organ donation system (if one exists). In under-developed countries with little 
regulation surrounding living and deceased organ transplant, there is the opportunity for living 
donor monetary compensation (Bramstedt and Xu 2007). In China, it is not known where the 
majority of deceased organs come from due to the lack of transparency in Chinese organ 
donation programs (Bramstedt and Xu 2007).  
   Aside from an American patient traveling with an uncompensated, un-coerced, consented, 
living donor, the origin of organs available for transplant tourists is ethically questionable at best. 
Residents of chronically underprivileged countries may feel forced into consenting to donation 
when they are unable to feed their families, or do not feel comfortable saying no to their 
government officials (Bramstedt and Xu 2007). There are also sanitation risks at many hospitals 
in countries with underdeveloped healthcare systems. Transplant tourists often face 
complications after returning to the United States (Bramstedt and Xu 2007). Infections, rejection 
secondary to poor donor/recipient matching services, incomplete medical records, and an 
inability to pay for expensive American aftercare are all issues related to transplant tourism 
(Bramstedt and Xu 2007). However, if an American transplant patient is unconcerned with the 
ethical and medical risks associated with transplant tourism, or has a living donor willing to 
travel with her who is also unconcerned with the medical risks, transplant tourism does result in 
cheaper transplant surgeries and remains an option for some American patients (Bramstedt and 
Xu 2007).  
 
 
CONCLUSION: TRANSPLANTS WITHOUT BARRIERS 
 
   Obviously, with the shortage of transplantable organs some patients will inevitably die on or 
off transplant waiting lists; however, without financial barriers, it won’t be because of their 
inability to pay. Transplantation programs without financial barriers give hope to terminally ill 
patients and their families. Despite the lack of financial barriers to transplant as seen in countries 
like Spain, Italy, the United Kingdom, and Japan, other barriers to donation exist, resulting in 
overall lower numbers of transplants in these countries. Reducing the financial barriers to 
transplant in the United States is a step in the right direction for medical ethics and patient 
equality. The reduction of financial barriers combined with the culture of donation in the United 
States and Spain could result in a donation and transplantation system that truly seeks to save 
lives, lacking profit and market driven motives. As we take steps to decrease financial barriers to 
organ transplant, we may see an increase in the amount of transplantable organs as donors and 
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their families give consent, knowing that the process is truly free of financial influence. Putting 
the politics of healthcare finance ahead of the importance of saving lives does a disservice to 
American transplant patients who otherwise have access to the best medical care in the world. 
Until there is radical change in the funding methods for organ donation in the United States, 
patients will continue to die because they are not considered eligible for a transplant based on 
their financial status. The American healthcare system’s bond to the financial market will 
prevent OPOs and transplant surgeons from saving lives more valuable than the almighty dollar.  
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